Jason Cohen

About the Author Jason Cohen

Jason is a Smarter Analyst editor and writer, who specializes in biotech and cannabis-based pharmaceutical companies.

Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

3 Biotech Stocks That Could Explode Higher in 2019

Black Friday is past. So is Cyber Monday.

Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …

Theravance’s (TBPH) COPD Drug Wins FDA Approval

Today, the FDA approved Theravance’s (TBPH) Yupelri (revefenacin) inhalation solution for the treatment of COPD. Thervance and Mylan (MYL) are partnered on the opportunity.

What to Do with Omeros (OMER) Stock Following 20% Sell-Off?

Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.

AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount

Shares of biotechnology company AcelRx (ACRX) are tumbling – down nearly 17% as of this writing. The reason?

Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …

Advanced Micro Devices (AMD) Stock Divides Analysts After Next Horizon Conference

Advanced Micro Devices (AMD) shares rose nearly 4% yesterday after the chip giant’s Next Horizon event kicked off with the announcement that the first …

Here’s Why This Analyst Boosted Price Target for Amarin (AMRN) Stock

Amarin (AMRN) investors should expect material news on November 10, as that’s when the fish oil drug maker plans to release additional details from …

J.P. Morgan Pours Cold Water on Puma Biotechnology (PBYI) Stock

Investors weren’t impressed with Puma Biotechnology (PBYI) latest earnings report, and at least one Wall Street analyst has had enough. J.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts